Drugmaker LIVation is pushing back against allegations by Novo Nordisk Inc., which claims that the Connecticut-based company violated trademark and unfair trade practices laws. The accusations stem from LIVation’s online comparisons of its compounded drugs to Ozempic, a product by Novo Nordisk. In response to these claims, LIVation has reportedly removed the disputed online content that Novo Nordisk had contested back in April. LIVation argues that with the posts now deleted, Novo Nordisk cannot demonstrate any ongoing harm as a result of those comparisons.
Details about the legal argumentation and further developments on this case can be found in an article by Law360.